IP Library Granted Patent US 7,799,345
Granted Patent B2
US 7,799,345 · App. 11/826,994 · Granted Sep 21, 2010

Preparation of injectable suspensions having improved injectability

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,799,345
App. No.
11/826,994
Granted
Sep 21, 2010
Kind
B2
Abstract

Injectable compositions having improved injectability. The injectable compositions include microparticles suspended in an aqueous injection vehicle having a viscosity of at least 20 cp at 20° C. The increased viscosity of the injection vehicle that constitutes the fluid phase of the suspension significantly reduces in vivo injectability failures. The injectable compositions can be made by mixing dry microparticles with an aqueous injection vehicle to form a suspension, and then mixing the suspension with a viscosity enhancing agent to increase the viscosity of the fluid phase of the suspension to the desired level for improved injectability.

Claims (14)

1. A composition for injection through a needle into a host, consisting of:

microparticles consisting essentially of naltrexone and a polymeric binder selected from the group consisting of poly(glycolic acid), poly-d,l-lactic acid, poly-l-lactic acid, copolymers of the foregoing, poly(aliphatic carboxylic acids), copolyoxalates, polycaprolactone, polydioxanone, poly(ortho carbonates), poly(acetals), poly(lactic acid-caprolactone), polyorthoesters, poly(glycolic acid-caprolactone), polyanhydrides, and polyphosphazines; and

an injection vehicle, wherein said injection vehicle consists of water, a viscosity enhancing agent, a wetting agent, and a tonicity adjusting agent, and wherein said microparticles are suspended in said injection vehicle at a concentration of more than about 30 mg/ml and up to about 300 mg/ml to form a suspension, wherein a fluid phase of said suspension has a viscosity greater than 30 cp and less than 600 cp at 20° C., wherein the viscosity of said fluid phase of said suspension provides injectability of the composition into the host through a needle ranging in diameter from 18-22 gauge.

2. The composition of claim 1 , wherein the polymeric binder is a copolymer of poly(glycolic acid) and poly-d,l-lactic acid.

3. The composition of claim 1 , wherein the viscosity enhancing agent is sodium carboxymethyl cellulose.

4. The composition of claim 1 , wherein the wetting agent is selected from the group consisting of polysorbate 20, polysorbate 40, and polysorbate 80.

5. The composition of claim 1 , wherein the tonicity adjusting agent is sodium chloride.

6. The composition of claim 1 , wherein the injection vehicle consists of water, sodium carboxymethyl cellulose, polysorbate 20, and sodium chloride.

7. The composition of claim 1 , wherein a mass median diameter of the microparticles is less than about 250 μm.

8. The composition of claim 7 , wherein the mass median diameter of the microparticles is in the range of from about 20 μm to about 150 μm.

9. The composition of claim 1 , wherein the polymeric binder is poly(lactide-co-glycolide), and the injection vehicle consists of water, sodium carboxymethyl cellulose, polysorbate 20, and sodium chloride.

10. The composition of claim 9 , wherein a mass median diameter of the microparticles is less than about 250 μm.

11. The composition of claim 10 , wherein the mass median diameter of the microparticles is in the range of from about 20 μM to about 150 μm.

12. The composition of claim 1 , wherein the polymeric binder is poly(d,l-lactide-co-glycolide) having a molar ratio of lactide to glycolide in the range of from about 85:15 to about 50:50.

Assignments (6)
RELEASE OF PATENT SECURITY AGREEMENT (FIRST LIEN) Recorded Dec 24, 2024
From: MORGAN STANLEY SENIOR FUNDING, INC.
To: ALKERMES, INC.; ALKERMES PHARMA IRELAND LIMITED
Reel/Frame 069771/0548 →
RELEASE BY SECURED PARTY (SECOND LIEN) Recorded Oct 12, 2012
From: MORGAN STANLEY SENIOR FUNDING, INC.
To: ALKERMES, INC.; ALKERMES PHARMA IRELAND LIMITED; ALKERMES CONTROLLED THERAPEUTICS INC.
Reel/Frame 029116/0379 →
CONFIRMATORY ASSIGNMENT Recorded Dec 12, 2011
From: ALKERMES CONTROLLED THERAPEUTICS INC.
To: ALKERMES PHARMA IRELAND LIMITED
Reel/Frame 027366/0141 →
PATENT SECURITY AGREEMENT (FIRST LIEN) Recorded Sep 29, 2011
From: ALKERMES, INC.; ALKERMES PHARMA IRELAND LIMITED; ALKERMES CONTROLLED THERAPEUTICS INC.
To: MORGAN STANLEY SENIOR FUNDING, INC.
Reel/Frame 026994/0186 →
PATENT SECURITY AGREEMENT (SECOND LIEN) Recorded Sep 29, 2011
From: ALKERMES, INC.; ALKERMES PHARMA IRELAND LIMITED; ALKERMES CONTROLLED THERAPEUTICS INC.
To: MORGAN STANLEY SENIOR FUNDING, INC.
Reel/Frame 026994/0245 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 8, 2008
From: RAMSTACK, J. MICHAEL; RILEY, M. GARY I.; ZALE, STEPHEN E.; HOTZ, JOYCE M.; JOHNSON, OLUFUNMI L.
To: ALKERMES CONTROLLED THERAPEUTICS, INC. I
Reel/Frame 020774/0421 →